A groundbreaking study from Dana-Farber Cancer Institute and Mass General Brigham has introduced an AI-based noninvasive tool to predict the spread of oropharyngeal cancer, a type of head and neck cancer. Published in the Journal of Clinical Oncology, this tool helps identify patients who may require aggressive treatments or be suitable for clinical trials involving immunotherapy. Dr. Benjamin Kann, a senior author, emphasizes its role in stratifying treatment options, including potential de-intensification strategies. The AI analyzes imaging data from CT scans to predict the presence of pathologic extranodal extension (ENE), which often indicates worse prognosis. Tested on over 1,700 patients, the tool improved risk stratification and survival predictions when integrated with existing clinical assessments. This innovative technology positions itself as a pivotal prognostic biomarker, promising to enhance staging and treatment planning for oropharyngeal cancer patients.
Source link
Share
Read more